Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fidelity shows number of shares available to short and the interest rate they charge in the quote box. I have to call them to find out what they are paying share owners to lend shares.
Fidelity will not loan an account owners shares to shorts unless a Fully Paid Lending Program agreement is signed by the account owner, unless the account owner has a margin balance. If there is a margin balance, the account owner doesn't fully own the shares.
I know people that use other brokers and have been told that their brokers call them when they would like to borrow shares. Much like sokol was called today.
Fidelity told me that one of the reasons they will not loan out fully paid shares is because the shares are no longer insured by the SPIC (initials from memory) once they are loaned.
I loaned shares of another security in the past. What Fidelity does (after the Fully Paid Lending Agreement is signed) is set up an account in my name at Wells Fargo Bank. Each trading day Fidelity deposits or withdraws money from that account to match the value of my loaned shares at the market close.
I owned shares of a different company and posted on that board. One of the posters busted his broker for lending his shares without his permission. There was something on his account statement that tipped him off. He hired a securities lawyer and was able to get payment for the interest owed to him plus a settlement. Sounds to me like there is a law against brokers lending account holders fully paid shares, but, I don't know that there is.
AVXL shares are valuable in the securities market right now because the shorts are having a hard time finding shares to borrow.
Last Thursday Fidelity was paying 5% to anyone that would lend their shares and charging the shorts 10.75%. On Friday the interest rate paid to those willing to lend went to 7%. On Monday the rate went to 9.25%.
Today Fidelity is charging the shorts 29.75% to borrow. I didn't check on what they were paying share owners to lend their shares.
Wow, you have the patience of a saint. You probably have more longevity in this stock than anyone here.
Things are moving quickly now.
GL to you and the patients.
Thanks for the additional info -
Your statement; "in some experiments we expect", has me thinking that you my have working experience with clinical trials.
Whether you do or don't, I'd like to know what you reaction is to the patients and caregivers feedback to Anavex.
I thought the feedback was an early indication of efficacy and that it was very unusual for patients to ask for a trial extension.
Thanks again -
I feel confident that statistical significance will improve with dose optimization.
From fall presentation -
ANAVEX™2--73 data is from 12 patients at baseline and day 36 with on--off--on dosing regimen without any dose optimization
How long have you been here? I've been here since April.
So, you are saying that p<0.005 is a statistically significant number, correct?
Is a p number only assigned to a statistically significant number?
TIA
Ah, yes, 12 patients = statistically insignificant. The science challenged hit piece author's buzz words that got play on this board AGAIN.
Statistically insignificant to who? Not me, not Dr. Missling!!!
Dr. Missling's statements from his oral presentation on 9/23. Remember these statements came 2 months after the 7/22 data release. Much more was known by the Doctor than on 7/22 -
What is also important to appreciate, effect was shown in 12 patients and 10 of 12 had an improvement of the signal. So, relatively robust. Not a skewed statistical effect.
The good doctor also chimed in with this music to the ears during his 9/23 oral presentation -
Physicians have told us that the safety profile is stronger than donepezil, the bestselling drug on the market.
I urge everyone to comment on the BS article. Here's my comment -
Anavex 2-73 is targeting the cause of AD, not the symptoms. The preclinical and first data show remarkable results. The 99.6% trial failure rate is derived from drugs that targeted the symptoms.
CEO Dr. Missling -
Christopher U. Missling, MS, PhD, MBA
Dr. Missling, President and CEO of Anavex™, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.
Stockpalooza paid by 3rd party, not Anavex.
A fair assessment of the Company could have been written after the 11/7 trial data release. To attempt to punish the share price this close to the major trial results smells of short desperation.
If Anavex has touted A3-71 as a possible preventative, I missed it. Here's good info on A2-73 being a possible preventative -
http://www.anavex.com/?news=anavex-2-73-could-prevent-alzheimers-disease-in-addition-to-modifying-and-treating-symptoms
Pre-clinical Study Demonstrates ANAVEX 2-73’s Ability to Preserve Mitochondrial Integrity and Block the Oxidative Stress and Cell Death that Leads to Amyloid-Beta Overproduction and Tau Hyperphosphorylation
NEW YORK, NY – February 25, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a research report in the current issue of peer-reviewed scientific journal Frontiers in Cellular Neuroscience. Among its conclusions, the report reveals that ANAVEX 2-73 prevents mitochondrial dysfunction and blocks resulting oxidative stress and apoptosis (cell death) in a nontransgenic mouse model of Alzheimer’s disease (AD). Mitochondrial damages have been consistently reported as an early cause of AD and appear before amyloid-beta plaques and memory decline in Alzheimer’s patients and transgenic mice. Thus, by preserving mitochondrial functionality and reducing other key AD hallmarks, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
“We provided clear evidence that the neuroprotective activity of sigma-1 receptor agonists, including the mixed muscarinic ligand/sigma-1 agonist ANAVEX 2-73, involves mitochondrial protection in AD models. Indeed, the drug efficiently protected mitochondria against amyloid-beta caused impairment of mitochondrial respiration, the key energy producing process within the cell,” said Tangui Maurice, PhD, one of the study authors and CNRS Research Director, Head of Team 2 ‘Endogenous Neuroprotection in Neurodegenerative Diseases’, at the University of Montpellier and INSERM. “Mitochondrial dysfunction and resulting oxidative stress are critical hallmarks of Alzheimer’s disease pathology and believed responsible for increased amyloid-beta production and Tau hyperphosphorylation.”
“We are encouraged by this study, which points to the potential ability of ANAVEX 2-73 to not only protect neurons from oxidative stress and amyloid-beta overproduction, which can cause toxicity and follow-on damage, but also the ability to possibly prevent the onset of the disease,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Our approach targets Alzheimer’s disease further upstream and apparently blocks these disease hallmarks, which may be a more promising approach. Combined with earlier findings that ANAVEX 2-73 restores mitochondrial functionality, this new report strengthens our compound’s potential in Alzheimer’s disease to also potentially act as a preventative drug.”
The report, entitled “Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model,” was jointly conducted by Valentine Lahmy, Romain Long, Didier Morin, Vanessa Villard and Tangui Maurice from the University of Montpellier and INSERM, the University of Paris-Est, Henri Mondor Institute, INSERM and Amylgen. The full paper is available on the Anavex website at www.anavex.com/publications/.
http://www.anavex.com/wp-content/uploads/9A9B8DB2.pdf
Great post! As an add on, try to imagine what AD prevention would do for the aging population and AVXL. Preventative use is not in sight yet, but possible.
From Anavex -
About ANAVEX 2-73
ANAVEX 2-73 is the investigational drug in the Phase 2a trial and is the Company’s lead investigational oral treatment for Alzheimer’s. It targets sigma-1 and muscarinic receptors, which is believed through upstream action to reduce protein misfolding, beta amyloid, tau and inflammation. Preclinical data indicates that ANAVEX 2-73 has the potential to prevent, halt and/or reverse the course of Alzheimer’s disease.
Another add on, PCYC partnered with J&J in 2011. The $21 billion sales price was after PCYC had given up 50% of profits in a partnership -
PCYC was in early and mid-stage studies when they partnered with Janssen Biotech (JNJ).
Pharmacyclics Scores Big With Janssen Biotech Deal
Dec 12 2011, 10:13 by: The Burrill Report | includes: JNJ, PCYC
By Marie Daghlian
Janssen Biotech, a unit of Johnson & Johnson (JNJ), is paying Pharmacyclics (PCYC) $150 million upfront for rights to co-develop and market its lead anti-cancer compound PCI-32765. The first-in-class oral Btk inhibitor blocks signaling in a critical pathway needed for tumor growth and proliferation. It is currently in early- and mid-stage studies across a variety of blood cancers, including non-Hodgkin’s lymphoma.
In addition to the upfront payment of $150 million, Sunnyvale, California-based Pharmacyclics will be entitled to receive up to $825 million in development and regulatory milestone payments. The companies have agreed to share development costs for oncology and other indications, excluding inflammation and immune-mediated conditions, with Pharmacyclics paying for 40 percent of the costs and Janssen picking up the rest. The partners will share profits equally in a 50/50 profit-loss agreement. Both companies will book revenue, Pharmacyclics in the United States and Janssen in the rest of the world.
The deal is expected to be slightly dilutive to Johnson & Johnson's 2011 earnings per share on the order of approximately 4 to 5 cents. William Hait, global head of cancer therapeutics for Janssen, said in a statement that PCI-32765 has broad applicability and the partnership is an “opportunity to bring a new form of oral therapy to patients with B-cell malignancies.”
Pharmacyclics has no marketed products. Its first product candidate, an injectable cancer drug, was rejected by U.S. regulators in 2007. Although the deal gives Pharmacyclics a hefty upfront payment, investors were not thrilled by the deal. Several analysts issued downgrades for the company citing its lack of revenues, and a market cap almost equal to the potential deal size.
Will Anavex‘s ticker symbol change?
Anavex‘s common stock will temporarily trade under the ticker symbol “AVXLD” for a period of 20 business days after the effective date of the reverse stock split to signify that the reverse stock split has occurred. After that time or earlier once NASDAQ approves the uplisting requirements, the “D” will be removed and our Company’s symbol will once again be “AVXL.”
Proposed Uplisting to NASDAQ Capital Market
What is the process for uplisting after the reverse stock split?
Our proposed listing on the NASDAQ Capital Market is subject to review by NASDAQ and dependent upon the company meeting certain listing requirements, including the maintenance of a minimum closing price of our common stock of $3.00 or more for at least five trading days. The company’s common stock will begin trading in the marketplace on a split-adjusted basis upon FINRA’s approval of the reverse stock split. After the reverse stock split, should NASDAQ approve our listing application, it is expected to take approximately 5-10 business days to complete the listing process.
Total O/S = 31,100,000
http://www.anavex.com/investors/faq-reverse-stock-split/
Yes, I know and I agree.
Yes, the data to be presented is definitely new -
NEW YORK, NY – October 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015. The late-breaking oral session will be presented by the trial’s Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia.
Presentation Details
Title: New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients
Date/Time: Saturday, November 7, 2015
9:45 a.m. Central European Time (3:45 a.m. Eastern Time)
Location: Gran Hotel Princesa Sofia, Barcelona, Spain
The multicenter Phase 2a clinical trial of ANAVEX 2-73 consists of two parts and a total of 32 mild-to-moderate Alzheimer’s patients. PART A is a simple randomized, open-label, two-period, cross-over, adaptive trial lasting up to 36 days for each patient. PART B is an open-label extension for an additional 52 weeks.
The primary objective of the trial is to evaluate the maximum tolerated dose of ANAVEX 2-73. Secondary trial objectives include exploratory cognitive efficacy using mini-mental state examination score (MMSE), dose response, bioavailability, Cogstate and electroencephalographic (EEG) activity, including event-related potentials (EEG/ERP), as well as the relationship of ANAVEX 2-73 as an add-on therapy to donepezil (Aricept®).
The original title told us what's being presented. The MMSE is measured in Part B. The other Cognitive Markers may be Part A and Part B. We'll probably never know why AVXL changed the title. I still think they were asked to change it so as to not steal all the thunder from the other presenters ahead of time.
Original title-
OC49 - New Exploratory Alzheimer’s Drug ANAVEX 2-73: Clinical Cognitive Improvement observed in Mini Mental State Examination (MMSE) and other Cognitive Markers in a Phase 2a Study in mild-to- moderate Alzheimer’s Patients.
Steve Macfarlane, MD (1), Marco Cecchi, PhD (2), Dennis Moore, PhD (2), Paul Maruff, PhD (3), Anastasios Zografidis, PhD (4), Christopher Missling, PhD (4)
This data from the 7/22 data release was only preliminary -
Preliminary measured Mini Mental State Examination (MMSE) and Cogstate scale changes are consistent with the observed trend of the cognitive EEG/ERP effect. The safety profile of ANAVEX 2-73 during Phase 2a appears consistent with the Phase 1 data; additional clinical data of the trial will be presented at future medical meetings.
From 2013, more on pre-clinical and Anavex Life Sciences Corp. (AVXL.OB) Comments on FDA Plan to Expedite Approval of New Alzheimer's Drugs
As reported by the New York Times, drugs in clinical trials would qualify for approval if people with very early-stage Alzheimer's showed even subtle improvement in memory or reasoning tests. ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has successfully completed a Phase 1 clinical trial in humans.
http://www.biospace.com/News/anavex-life-sciences-corp-comments-on-fda-plan-to/290821
Yes stealthways, I thought that science related post was excellent. The pre-clinical results are more meaningful to me as well. Here's more of the epileptologist's posts -
http://finance.yahoo.com/mbview/userview/;_ylt=AhPSdISmu324bDbkfelkpLTeAohG;_ylu=X3oDMTB1cHB2cjA0BHBvcwMyBHNlYwNNZWRpYU1zZ0JvYXJkc1hIUlVsdA--;_ylg=X3oDMTBhYWM1a2sxBGxhbmcDZW4tVVM-;_ylv=3?&u=dadofmarcmax&bn=04bae8c0-3391-3115-ad23-19e486e82827&page=1
The MMSE is definitely measured during Part B -
Mini-mental state examination score (MMSE) [ Time Frame: Baseline, and during the extension period at Week 1, 12, 26, 38 and 52 ] [ Designated as safety issue: No ]
I haven't asked -
My guess is that the organizers of the conference wanted to save the fireworks for their conference.
Or -
Other presenting companies objected. With a headline like AVXL's original, there probably wouldn't be much interest in what the others were going to present.
The original headline for the CTAD presentation told me all I need to know -
AVXL is presenting at CTAD in Barcelona on November 7th, 2015 at 9:45 am. All the AVXL big hitters are going to be there. The 9:45am slot is marked as "Late Breaking Communication". AXON presents just before.
OC49 - New Exploratory Alzheimer’s Drug ANAVEX 2-73: Clinical Cognitive Improvement observed in Mini Mental State Examination (MMSE) and other Cognitive Markers in a Phase 2a Study in mild-to- moderate Alzheimer’s Patients.
Steve Macfarlane, MD (1), Marco Cecchi, PhD (2), Dennis Moore, PhD (2), Paul Maruff, PhD (3), Anastasios Zografidis, PhD (4), Christopher Missling, PhD (4)
I'm sure that Dr. Missling thought the SS author was misinformed and he decided to be proactive and set things straight.
He now knows that SS is a rag blog used by shorts to attack companies.
I don't blame the doctor for trying, instead of just taking the lazy way out by ignoring the hit piece.
I wish this stock was marginable today. I would definitely use it to buy a big chunk at $8.00.
Of course the shorts know it's not and are using that to their advantage during this bear raid.
A doctor (epileptologist - spelling?) posted this on another board. Sounds like he knows quite a bit about the science -
With all due respect - hope and greed are not the only thing this company and its investors have.
I don't think you have done your due diligence regarding the effectiveness of sigma 1 receptor agonists. If you read the preclinical data and delve deep into the mouse models of alzheimers - with the sigma 1 knock out mice vs. the mice on anavex 2-73 --- there are objective measures of tau protein markers that prove that the the drug works; that sigma 1 receptor agonists actually modify the pathologic process whereby brains get clogged with amyloid proteins/etc.
Sigma 1 receptor agonist - like anavex 2-73 actually reverses the amyloid aggregation and reverses the pathologic process.
Considering that mammals have similar neurophysiology (at the microscopic level - all nerves, synapses work the same) - the implication is obvious to the scientists amongst us (not you).........sigma 1 receptor agonists - like anavex 2-73 - is the first out of many previous failed drugs - to stop and reverse the pathophysiological process that can lead to neurodegenerative diseases - like Alzheimers.
Is this not a fundamental in your view?
Are the results from the prelim data - phase 2a in the summer a sham?
What the original poster was trying to convey - you can do all the TA you want - but if you ignore the science, you are doing so at your own risk. Objective Data and science ALWAYS beats subjective technical analysis in the longterm......PERIOD
Another point I meant to make -
If there is an offering, executing it before data release could put a black cloud over data until it is released. I don't think this point would be missed by Dr. Missling.
Yes, Dr. Missling may have already shared new data with prospective buyers and that may partially account for the recent share price surge.
I just think that if the data is remarkable again, Missling will release it to the public before an offering and make the buyers pay up. I believe he will make the most of the remarkable data.
All guess work on my part.
Hopefully, the 11/7 data will be as good or better than the 7/22 data. It should be, the 7/22 data was without dose optimization.
More remarkable data should raise the share price to $20. An offering to the right buyers should double the share price from there.
So, right, the double is from $20.
Very little chance of an offering before the 11/7 data release. Buyers of an offering would want to see those trial results before committing.
I think there will be a post 11/7 offering and it will be bought by the likes of Adage and Baker Brothers. A 10 million share offering at ~$20 would give AVXL a lot of options.
When funds, like those mentioned above, buy into emerging bios you can expect the share price to at least double.
Oops, see forgot to include this in her article. I'm sure it won't happen again -
NEW YORK, NY, July 22, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced initial positive cognitive data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation. Cognitive EEG/ERP P300 data, a real-time physiological measure of cognitive processes with demonstrated sensitivity to Alzheimer’s disease, is being presented today for the first 12 of 32 mild-to-moderate Alzheimer’s patients in the ongoing ANAVEX 2-73 Phase 2a clinical trial at AAIC 2015 in Washington, DC.
ANAVEX 2-73 showed in 83 percent (10/12) of patients positive cognitive effects during PART A of the study, which consists of a 36-day on-off-on not-yet-optimized dosing regimen to assess bioavailability. At day 36, the amplitude of the cognitive EEG/ERP biomarker P300 increased 38 percent from baseline. Published data suggests that a 38 percent increase is approximately 4 times higher than donepezil (Aricept®), the current standard of care, in the same timeframe.
Preliminary measured Mini Mental State Examination (MMSE) and Cogstate scale changes are consistent with the observed trend of the cognitive EEG/ERP effect. The safety profile of ANAVEX 2-73 during Phase 2a appears consistent with the Phase 1 data; additional clinical data of the trial will be presented at future medical meetings.
“This is the first time the investigational drug ANAVEX 2-73 has been administered to Alzheimer’s patients. In addition to the positive EEG/ERP P300 biomarker signal, the feedback we’ve had so far is that patients and care providers have noticed both cognitive and functional improvement, increased alertness, improvement in activities of daily living, greater organization and a requirement for less prompting,” said study’s principal investigator Dr. Stephen Macfarlane, FRANZCP, Associate Professor and Director of Aged Psychiatry at The Alfred Hospital. “Subsequent to the positive initial feedback, we are applying to expand the extension period from 26 weeks to 52 weeks at the request of the participants.”
“We are cautiously optimistic given the encouraging feedback and the preliminary cognitive data. We look forward to the full ANAVEX 2-73 Phase 2a trial results,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “As of today, we have enrolled two-thirds of the patients. We expect the trial to be fully enrolled and to have PART A completed by the end of the year.”
The poster entitled “New Exploratory Alzheimer’s Drug ANAVEX 2-73 Changes in Electrophysiological Markers in Alzheimer’s Disease – First Patient Data from an ongoing Phase 2a Study in mild-to-moderate Alzheimer’s Patients” was co-authored by Steve Macfarlane, Marco Cecchi, Dennis Moore, Anastasios Zografidis and Christopher Missling and is available on the publications page of the Anavex website.
About the ANAVEX 2-73 Phase 2a Study
The ongoing, multicenter Phase 2a adaptive trial of ANAVEX 2-73 in both male and female mild-to-moderate Alzheimer’s patients seeks to enroll 32 patients. It started in January 2015 and the first 12 patients, most who are also taking donepezil, have completed PART A of the two-part trial. Lasting up to 36 days for each patient, PART A is a simple randomized, open-label, two-period trial with an on-off-on not-yet-optimized dosing regimen to assess bioavailability, and cross-over between oral (30mg/50mg) and IV (3mg/5mg) administration. Event-related potentials (EEG/ERP) are used to assess cognitive effects and optimize dosing of ANAVEX 2-73. PART B is an open-label extension for an additional 26 weeks, with daily oral dosing so as to establish a longer drug effect.
The primary endpoint of the Phase 2a trial is evaluation of the maximum tolerated dose of ANAVEX 2-73, which had shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Secondary endpoints are dose response, bioavailability, exploratory cognitive effects using electroencephalographic (EEG) activity, including event-related potentials (EEG/ERP), Mini Mental State Examination (MMSE), Cogstate and evaluation of ADSC-ADL and add-on therapy to donepezil, the current standard of care, which represents ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®).
Additional information regarding the trial is available from the U.S. National Institutes of Health (NIH) clinical trials database at www.clinicaltrials.gov.
About Alzheimer’s Disease
Today, Alzheimer’s disease remains the largest unmet medical need in neurology. More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care estimated to exceed $200 billion annually. By 2050, 100 million people are expected to be living with the disease. Alzheimer’s disease is a neurological disorder generally characterized by memory loss and cognitive decline. A neurodegenerative form of dementia, the disease begins with mild symptoms and becomes progressively worse.
About AAIC
The Alzheimer’s Association International Conference® (AAIC) is the world’s largest forum for the dementia research community. International investigators, clinicians and care providers gather annually to share the latest study results, theories and discoveries to bring the world closer to breakthroughs in dementia science. As part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in convulsive epileptic animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Further information is available at www.anavex.com.
That rag hit piece site and their followers got their ass handed to them last week didn't they!
A totally incoherent site that doesn't allow facts to be presented in comments. SHAME!!!
Every stock investment comes with risk, including the blue chips. GE's stock price fell from the 40s to 6 bucks during the financial crisis. A $5 billion loan from Warren Buffet saved GE's butt.
Applying a huge risk profile to AVXL is a huge mistake, IMHO. There's only a very small chance that 2-73 Plus won't outperform donepezil and become the Standard of Care for Alzheimer's patients.
Anavex discovered that Anavex 2-73 Plus worked much better than 2-73 alone. Their current trial has 2-73 being given to patients that are mostly already taking donepezil.
It takes time to fully vet a new combo and get a trial started.
Also, Missling was appointed CEO in 2013. He promptly raised the money needed for a more intelligent Phase 1 trial and the current Phase 2a trial.
Oh, come on you guys, it was a joke related to an earlier post!
It took some searching, but I finally found the penny promo -
NEW YORK, NY – August 10, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop ANAVEX 2-73 for the treatment of Parkinson’s disease.
The MJFF grant is expected to fully fund a preclinical study on the effect of ANAVEX 2-73 in a Parkinson’s disease animal model, which seeks to provide a solid dataset that will justify moving forward to clinical development in Parkinson’s. The study may also provide further evidence for the involvement of sigma-1 receptors in potentially disease-modifying therapies for Parkinson’s disease.
As a potential platform drug and the Company’s lead therapeutic, ANAVEX 2-73 targets misfolded proteins central to many neurodegenerative diseases, including Parkinson’s and Alzheimer’s. It is believed to enhance the body’s own cellular defense mechanisms through both sigma-1 and muscarinic receptors to return diseased cells to a pre-diseased or “homeostatic” state.
“The development of disease-modifying therapies for Parkinson’s disease is the top priority of The Michael J. Fox Foundation and ANAVEX 2-73 presents a promising approach,” said Marco Baptista, PhD, Senior Associate Director of MJFF Research Programs. “Companies that receive funding from MJFF have scientifically compelling plans that hold obvious potential to impact our understanding of Parkinson’s and ultimately the development of improved treatments for people with the disease. To that end, we look forward to the results of the ANAVEX 2-73 study.”
“If successful, this study will accelerate the translation of preclinical findings into the very first clinical trial of ANAVEX 2-73 as a potential disease-modifying therapy for Parkinson’s disease,” said Angela Cenci, MD, PhD, and Professor at Lund University, where the study will be conducted. “We are in the fortunate position that ANAVEX 2-73 has already been tested for safety and tolerability in humans, and was found to be a good clinical drug candidate.”
“Anavex is honored to have The Michael J. Fox Foundation for Parkinson’s Research support the development of our technology and we are pleased to be collaborating with such a prestigious organization,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We hope this research will lead to improved therapies that can maximize the benefits and minimize side effects for Parkinson’s patients. After reporting positive initial data last month in our ongoing ANAVEX 2-73 Phase 2a clinical trial in Alzheimer’s patients, we expect the trial to be fully enrolled and to have PART A completed by the end of the year. Our work with MJFF underscores our unwavering commitment to delivering new medications for neurological disorders characterized by deposits of misfolded proteins, including both Parkinson’s and Alzheimer’s diseases.”
The preclinical study of ANAVEX 2-73 in Parkinson’s disease will be conducted at Lund University in Sweden under supervision of Professor Angela Cenci, MD, PhD.
Market Cap = O/S X share price
Fully Diluted Market Cap = O/S + Options + Warrants X share price
Nice day here today on day one of the up list and count down to pivotal data release rally.
Lots more upside on the way!
Yes Mikesc,
Best drug on the planet - Moving to NASDAQ - Only ~42 million shares fully diluted!!!
AVXL closed at $1.45 today. The price moved up from $1.37 during the last 6 minutes.
It's unfortunate that news of the reverse split "leaked" before it was accompanied by the Company's PR stating that it was finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. At the time of the "leak", AVXL was trading in the mid $1.60s.
The PR states NASDAQ Capital Market -
NEW YORK, NY – October 6, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares. The Company's common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015.
Their up list was on 4/17. Their reverse split announcement was much the same as ours -
InVivo Therapeutics announces implementation of reverse stock split in preparation for planned uplisting to NASDAQ
8:02 AM ET 4/8/15 | Briefing.com
Co announced the implementation of its previously disclosed 1-for-4 reverse stock split as of today, April 8, 2015, a key step in preparation for its planned uplisting to the NASDAQ Capital Market.The company's common stock will begin trading on a post-split basis at market open today, April 8, 2015, under the symbol "NVIVD," with the "D" added for 20 trading days to signify that the reverse stock split has occurred.